What are the guidelines for Pap (Papanicolau) testing for a female patient between 21 and 65 years old with a history of cervical cancer, HIV (Human Immunodeficiency Virus) infection, or immunosuppression?

Cervical Cancer Screening Guidelines for Women 21-65 Years with Special Risk Factors

Standard Screening for Average-Risk Women (21-65 Years)

For women aged 21-29 years without HIV, immunosuppression, or history of cervical cancer, screen with Pap test alone every 3 years. 1, 2, 3

For women aged 30-65 years without special risk factors, the preferred approach is co-testing (Pap plus HPV) every 5 years, with Pap alone every 3 years as an acceptable alternative. 1, 2, 3

Key Points for Average-Risk Women:

• Begin screening at age 21 years regardless of age of sexual debut or other risk factors 1, 2, 3
• Do not use HPV testing in women under 30 years, either alone or as co-testing 1
• HPV vaccination status does not change screening recommendations 1, 3
• Stop screening after age 65 if adequate prior negative screening is documented (≥3 consecutive negative Pap tests or ≥2 consecutive negative co-tests within the last 10 years, with the most recent test within 5 years) 1, 2, 3

---

Special Populations Requiring Modified Screening

Women with HIV Infection

Women with HIV require annual screening indefinitely, starting at age 21 or within 1 year of sexual debut (whichever comes first), and screening should never be discontinued regardless of age. 4, 2

HIV-Specific Protocol:

• Screen twice during the first year after HIV diagnosis, then annually thereafter 4
• After 3 consecutive years of normal cytology results, the screening interval can be extended to every 3 years 4
• Use conventional or liquid-based cytology as the primary screening method; primary HPV testing alone is not recommended 4
• Co-testing can be performed in women aged 30 years or older with HIV 4
• Lifelong screening is required with no age at which to discontinue 4, 2

The rationale for this intensive surveillance is that HIV infection confers immunocompromised status, placing patients at substantially higher risk for HPV persistence and progression to cervical dysplasia. 4 Adolescents with HIV demonstrate a high rate of progression of abnormal cytology, unlike immunocompetent adolescents, warranting earlier screening. 4

Women with Immunosuppression (Non-HIV)

Women with chronic immunosuppression (including transplant recipients) require annual screening indefinitely, regardless of age. 2

• These patients are explicitly excluded from standard cervical cancer screening guidelines 4
• Follow the same intensive surveillance protocol as HIV-positive women 2

Women with History of Cervical Cancer or High-Grade Lesions

Women with a history of CIN2, CIN3, or adenocarcinoma in situ must continue screening for at least 20 years after treatment, even if this extends past age 65 years. 1, 2

• After spontaneous regression or appropriate management of these lesions, routine screening should continue for at least 20 years 1
• Do not discontinue screening at age 65 in these women 2

---

Common Pitfalls to Avoid

Critical Errors in Special Populations:

• Never apply standard screening intervals to HIV-positive or immunosuppressed women 4, 2
• Never use primary HPV testing alone in people with HIV; cytology should be the primary screening method 4
• Never discontinue screening at age 65 in HIV-positive women or those with history of high-grade lesions 4, 2
• Never delay screening until age 21 if sexual activity began earlier in adolescents with HIV; screen 1 year after sexual debut 4

General Screening Errors:

• Do not use HPV testing (alone or as co-testing) in women under 30 years 1, 3
• Do not screen women under age 21 regardless of sexual activity history 1, 2, 3
• Do not continue standard screening intervals in women who have had total hysterectomy with cervix removal for benign reasons and no history of high-grade lesions 2, 3

---

Management Algorithm Summary

Step 1: Identify Risk Category

• HIV-positive or immunosuppressed → Annual screening indefinitely 4, 2
• History of CIN2/CIN3/AIS → Continue screening for 20 years post-treatment 1, 2
• Average risk → Age-based standard screening 1, 2, 3

Step 2: Apply Age-Appropriate Protocol

• Age 21-29 (average risk): Pap alone every 3 years 1, 2, 3
• Age 30-65 (average risk): Co-testing every 5 years (preferred) or Pap alone every 3 years 1, 2, 3
• Age >65 (average risk with adequate prior screening): Discontinue 1, 2, 3

Step 3: Special Considerations

• HIV/immunosuppressed patients: Never discontinue screening 4, 2
• History of high-grade lesions: Screen for 20 years post-treatment 1, 2
• Total hysterectomy with cervix removal (benign indication, no high-grade lesions): Discontinue screening 2, 3